Summary & Overview

Other Injury, Poisoning and Toxic Effect Diagnoses without MCC: Inpatient Reimbursement Overview

DRG 923 includes admissions for other injury, poisoning, and toxic effect diagnoses without Major Complication or Comorbidity; it covers less complex injury or poisoning cases that do not trigger higher-severity groupings. This grouping matters for inpatient reimbursement because the Diagnosis-Related Group assignment determines Medicare prospective payment levels and reflects expected resource consumption for these lower-severity cases.

Other Injury, Poisoning and Toxic Effect Diagnoses without MCCDRG Other Injury, Poisoning and Toxic Effect Diagnoses without MCCDRG 923Diagnosis-Related GroupInpatient ReimbursementMedicareTraumaToxicologyEmergency MedicineHospital Coding

DRG 923 Overview

DRG 923 covers hospital admissions for other injury, poisoning, and toxic effect diagnoses without Major Complication or Comorbidity. This Diagnosis-Related Group groups patients with less severe injury or poisoning presentations that do not meet Major Complication or Comorbidity criteria, affecting expected resource use and length of stay. It matters for Medicare inpatient payment because the Diagnosis-Related Group assignment drives prospective payment rates and influences revenue for cases with lower clinical complexity. Accurate coding and documentation determine whether an admission is classified here versus a higher-paying Diagnosis-Related Group.

Summary & Overview

Other Injury, Poisoning and Toxic Effect Diagnoses without MCC: Inpatient Reimbursement Overview

DRG 923 Overview

Clinical Trials

Acute emergency intervention studies evaluating rapid diagnostic and management protocols for a heterogeneous group of non-MCC injury and poisoning admissions. These trials enroll patients presenting to the emergency department or admitted to inpatient units with acute injuries or toxic exposures that do not carry major complications (for example, moderate fractures, isolated burn injuries, or single-agent overdoses without organ failure). Research focuses on time-to-intervention, standardized triage pathways, and short-term clinical endpoints (length of stay, need for escalation of care), which is relevant to providers for optimizing initial care and to payers because efficient early management can reduce unnecessary resource use and readmissions.
Comparative effectiveness studies of inpatient medical and surgical management strategies for specific non-MCC injury diagnoses. These studies compare alternative operative versus nonoperative treatments, analgesic regimens, or wound-care approaches in defined subgroups (e.g., nondisplaced fractures, soft-tissue injuries, or localized toxic exposures) and measure functional recovery, complication rates, and inpatient resource utilization. Findings inform clinicians about best practice choices for similar-case patients and help payers evaluate which care pathways produce equivalent or superior outcomes at lower cost.
Post-discharge outcomes and care-coordination research assessing rehabilitation, follow-up adherence, and patient-reported outcomes after hospitalization for injury or poisoning without MCC. These prospective cohort or pragmatic trials follow patients after discharge to study factors that influence return to baseline function, subsequent healthcare use, and preventable readmissions—examining interventions like structured discharge planning, outpatient therapy referral models, or remote monitoring. This research is important to providers to improve continuity of care and functional outcomes, and to payers because improved post-discharge management can reduce downstream costs and utilization associated with complications or missed rehabilitation needs.

Related Codes

915-ALLERGIC-REACTIONS-WITH-MCC

Allergic Reactions with MCC: Inpatient Reimbursement Overview

908-OTHER-O-R-PROCEDURES-FOR-INJURIES-WITH-CC

Other O.R. Procedures for Injuries with CC: Inpatient Reimbursement Overview

918-POISONING-AND-TOXIC-EFFECTS-OF-DRUGS-WITHOUT-MCC

Poisoning and Toxic Effects of Drugs without MCC: Inpatient Reimbursement Overview

922-OTHER-INJURY-POISONING-AND-TOXIC-EFFECT-DIAGNOSES-WITH-MCC

Other Injury, Poisoning and Toxic Effect Diagnoses with MCC: Inpatient Reimbursement Overview

901-WOUND-DEBRIDEMENTS-FOR-INJURIES-WITH-MCC

Wound Debridements for Injuries with MCC: Inpatient Reimbursement Overview

909-OTHER-O-R-PROCEDURES-FOR-INJURIES-WITHOUT-CC-MCC

Other O.R. Procedures for Injuries without CC/MCC: Inpatient Reimbursement Overview

914-TRAUMATIC-INJURY-WITHOUT-MCC

Traumatic Injury without MCC: Inpatient Reimbursement Overview

904-SKIN-GRAFTS-FOR-INJURIES-WITH-CC-MCC

Skin Grafts for Injuries with CC/MCC: Inpatient Reimbursement Overview

919-COMPLICATIONS-OF-TREATMENT-WITH-MCC

Complications of Treatment with Major Complication or Comorbidity: Inpatient Reimbursement Overview

905-SKIN-GRAFTS-FOR-INJURIES-WITHOUT-CC-MCC

Skin Grafts for Injuries without CC/MCC: Inpatient Reimbursement Overview

Showing 1–10 of 19

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

OpenPayer

Summary & Overview

Other Injury, Poisoning and Toxic Effect Diagnoses without MCC: Inpatient Reimbursement Overview

DRG 923 Overview

OpenPayer

Summary & Overview

Other Injury, Poisoning and Toxic Effect Diagnoses without MCC: Inpatient Reimbursement Overview

DRG 923 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes